All In Biotech

Drug Trial Radar · NCT01966471

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer

Last checked: Nov 20, 2026Latest source record: Jun 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,846 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,846

Actual

Start

Jan 31, 2014

Primary completion

Nov 27, 2019

Study completion Jun 4, 2021

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 21, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant therapy in participants with human epidermal growth (HER) factor 2 (HER2)-positive primary invasive breast cancer. Following surgery and anthracycline-based chemotherapy, participants will receive either trastuzumab emtansine at a dose of 3.6 milligrams per kilogram (mg/kg) and pertuzumab at a dose of 420 milligrams (mg) intravenously (IV) every 3 weeks (q3w) or trastuzumab at a dose of 6 mg/kg and pertuzumab at a dose of 420 mg IV q3w in combination with a taxane.

Conditions

  • Breast Cancer

Interventions

  • Trastuzumab EmtansineDrug

    Trastuzumab emtansine IV infusion (duration 90 minutes) will be administered at 3.6 mg/kg q3w for up to 18 cycles (1 cycle = 21 days).

  • TrastuzumabDrug

    Trastuzumab IV infusion (duration 90 minutes) will be administered at 8 mg/kg loading dose followed by 6 mg/kg IV q3w for up to 18 cycles (1 cycle = 21 days).

  • PertuzumabDrug

    Pertuzumab infusion (duration 60 minutes) will be administered at 840 mg loading dose followed by 420 mg IV q3w for up to 18 cycles (1 cycle = 21 days).

  • PaclitaxelDrug

    IV infusion of paclitaxel 80 mg/m\^2 once weekly may be administered concurrently with trastuzumab in combination with pertuzumab for 12 weeks.

  • EpirubicinDrug

    3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using epirubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.

  • DoxorubicinDrug

    3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.

  • DocetaxelDrug

    IV infusion either docetaxel every 3 weeks (q3w) (at 100 milligram per square meter \[mg/m\^2\] for 3 cycles (1 cycle = 21 days); at 75 mg/m2 for 4 cycles; or start at 75 mg/m\^2 in the first cycle and escalate to 100 mg/m\^2 if no dose limiting toxicity occurs, for a total of 3 cycles at minimum) may be administered concurrently with trastuzumab in combination with pertuzumab.

  • CyclophosphamideDrug

    3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.

  • 5-FluorouracilDrug

    3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using 5-fluorouracil, may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-Free Survival (IDFS) in the Node-Positive SubpopulationTime frame: Last participant randomized to data cut-off date of 27 November 2019 (approximately 70 months). The 3 year IDFS event-free rate was assessed based on the data collected for each participant considering the cut-off date mentioned above.
  2. Invasive Disease-Free Survival (IDFS) in the Overall PopulationTime frame: First participant randomized up to approximately 7.5 years

Locations

295 sites in 36 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute - Bisgrove

    Scottsdale, Arizona

  • Kaiser Permanente - Oakland

    Oakland, California

  • Kaiser Permanente - Roseville; Oncology Pharmacy

    Roseville, California

  • Kaiser Permanente - Sacramento; Oncology Pharmacy

    Sacramento, California

  • UC Davis Cancer Center; Oncology

    Sacramento, California

  • Southern California Kaiser Permanente

    San Diego, California

  • Kaiser Permanente - San Jose

    San Jose, California

  • Kaiser Permanente - San Leandro

    San Leandro, California

  • Kaiser Permanente - South SF; Oncology Clinical trials

    South San Francisco, California

  • Stanford University School of Medicine

    Stanford, California

  • Kaiser Permanente - Vallejo

    Vallejo, California

  • Kaiser Permanente - Walnut Creek; Oncology Pharmacy

    Walnut Creek, California

  • Holy Cross Hospital

    Fort Lauderdale, Florida

  • Florida Cancer Specialists; SCRI

    Fort Myers, Florida

  • Florida Cancer Specialists; Saint Petersburg

    St. Petersburg, Florida

  • University Cancer & Blood Center, LLC; Research

    Athens, Georgia

  • Georgia Cancer Specialists

    Atlanta, Georgia

  • Central Georgia Cancer Care PC

    Macon, Georgia

  • Quincy Medical Group; Canc Ctr at Blessing Hosp

    Quincy, Illinois

  • Carle Cancer Center

    Urbana, Illinois

  • Indiana University

    Indianapolis, Indiana

  • Cancer Center of Kansas

    Wichita, Kansas

  • Anne Arundel Health System Research Instit-Annapolis Oncology Ctr

    Annapolis, Maryland

  • Mercy Medical Center

    Baltimore, Maryland

  • Dana Farber Cancer Inst.

    Boston, Massachusetts

  • Beth Israel Deaconess Med Ctr

    Boston, Massachusetts

  • Karmanos Cancer Institute..

    Detroit, Michigan

  • Henry Ford Hospital; Hematology Oncology

    Detroit, Michigan

  • US oncology research at Minnesota Oncology

    Saint Paul, Minnesota

  • Mercy Medical Research Institute

    Springfield, Missouri

  • Dartmouth Hitchcock Med Center

    Lebanon, New Hampshire

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Memorial Sloan-Kettering Cancer Center

    Commack, New York

  • ProHEALTH Care Associates LLP

    Lake Success, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Cone Health Cancer Center

    Greensboro, North Carolina

  • Oncology Hematology Care Inc

    Cincinnati, Ohio

  • Mercy Clinic Oklahoma Communties, Inc

    Oklahoma City, Oklahoma

  • Magee-Woman's Hospital

    Pittsburgh, Pennsylvania

Showing 40 of 295 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.